In-vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori.
- Author:
Li-hua HE
1
;
Yan YIN
;
Yuan-hai YOU
;
Xiao-mei YAN
;
Jian-zhong ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; pharmacology; Enzyme Inhibitors; pharmacology; Esomeprazole; analogs & derivatives; pharmacology; Helicobacter pylori; drug effects; Lansoprazole; Microbial Sensitivity Tests; Proton Pump Inhibitors; Rabeprazole
- From: Chinese Journal of Epidemiology 2003;24(6):447-448
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the antimicrobial activity of Pariet, Tekpron, Nexium, respectively, against Helicobacter pylori (H. pylori) in vitro.
METHODSAntimicrobial effects of these medicines were evaluated through detection of MICs for 3 H. pylori strains isolated from different countries.
RESULTSThe MIC(99) contents were 2.25 mg/L, 42.5 mg/L and 360 mg/L, respectively, for the three medicines. The strains under testing exhibited the same susceptibility to each medicine. Nexium did not inhibit the bacteria under the concentration of 3.6 - 36 mg/L with more and bigger H. pylori colonies seen when compared with controls.
CONCLUSIONSThe growth inhibitory activity appeared to be different among the three PPI medicines under investigation, with Rabeprazole the most potential agent of the three. Data suggested that the action of growth inhibition in vitro was resting on the characteristic of the given PPI as well as the supplements of the medicine.
